Simonsen Jens B
Department of Chemistry and Nano-Science Center, University of Copenhagen, Copenhagen, Denmark.
Nanomedicine. 2016 Oct;12(7):2161-2179. doi: 10.1016/j.nano.2016.05.009. Epub 2016 May 26.
During the last decade, and with increasing intensity, the potential for using reconstituted high-density lipoprotein (rHDL) particles to deliver hydrophobic drugs to impaired cells and tissues has been explored. Here, we evaluate various parameters that should be considered when utilizing discoidal rHDL particles as a drug delivery platform. Key parameters such as preparation basics, pronounced statistical variation in drug incorporation across rHDL particles, effects of lipid composition on HDL/rHDL in vivo and vitro dynamics/particle stability, and pharmacokinetic/safety data from rHDL infusion studies in human subjects will be addressed including the innate receptors and native functions of HDL. The broad but detailed information presented in this work could also be deployed in other rHDL-related research. However, the major aim of this review is to point out factors that have the potential to advance rHDL research toward realizing the 'magic bullet' for lipophilic and hydrophilic drug delivery in various clinical contexts.
在过去十年中,人们对利用重组高密度脂蛋白(rHDL)颗粒向受损细胞和组织递送疏水药物的潜力进行了越来越深入的探索。在此,我们评估了将盘状rHDL颗粒用作药物递送平台时应考虑的各种参数。将讨论关键参数,如制备基础、rHDL颗粒间药物掺入存在明显的统计差异、脂质组成对HDL/rHDL体内外动力学/颗粒稳定性的影响,以及人体受试者rHDL输注研究的药代动力学/安全性数据,包括HDL的固有受体和天然功能。本研究中呈现的广泛而详细的信息也可应用于其他与rHDL相关的研究。然而,本综述的主要目的是指出那些有可能推动rHDL研究朝着在各种临床环境中实现亲脂性和亲水性药物递送的“神奇子弹”迈进的因素。